GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » ROE %

BioStem Technologies (BioStem Technologies) ROE % : Negative Equity% (As of Sep. 2023)


View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BioStem Technologies's annualized net income for the quarter that ended in Sep. 2023 was $1.47 Mil. BioStem Technologies's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $-4.05 Mil. Therefore, BioStem Technologies's annualized ROE % for the quarter that ended in Sep. 2023 was Negative Equity%.

The historical rank and industry rank for BioStem Technologies's ROE % or its related term are showing as below:

BSEM's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.44
* Ranked among companies with meaningful ROE % only.

BioStem Technologies ROE % Historical Data

The historical data trend for BioStem Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies ROE % Chart

BioStem Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioStem Technologies Quarterly Data
Sep15 Dec15 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - Negative Equity

Competitive Comparison of BioStem Technologies's ROE %

For the Biotechnology subindustry, BioStem Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's ROE % falls into.



BioStem Technologies ROE % Calculation

BioStem Technologies's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-7.075/( (-5.959+-4.076)/ 2 )
=-7.075/-5.0175
=N/A %

BioStem Technologies's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=1.468/( (-4.565+-3.526)/ 2 )
=1.468/-4.0455
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


BioStem Technologies  (OTCPK:BSEM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=1.468/-4.0455
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1.468 / 14.396)*(14.396 / 4.457)*(4.457 / -4.0455)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.2 %*3.23*N/A
=ROA %*Equity Multiplier
=32.95 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=1.468/-4.0455
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (1.468 / 1.468) * (1.468 / 2.12) * (2.12 / 14.396) * (14.396 / 4.457) * (4.457 / -4.0455)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.6925 * 14.73 % * 3.23 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


BioStem Technologies ROE % Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioStem Technologies (BioStem Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.